“…An alternative approach was suggested to be to complement the treatment in neuronal compartments with increasing the production of new neurons to provide resilience and strength to the diseased circuitry (Choi et al, 2018;Moreno-Jimenez et al, 2019;Mu and Gage, 2011;Tincer et al, 2016). Yet, neurogenesis in human brains is quite controversial (Arellano et al, 2018;Cipriani et al, 2018;Dennis et al, 2016;Duque and Spector, 2019;Sorrells et al, 2018). Although many reports documented the presence of adult neurogenesis in human brains (Boldrini et al, 2018;Ernst et al, 2014;Kempermann et al, 2018;Magnusson and Frisen, 2016;Moreno-Jimenez et al, 2019;Spalding et al, 2013), and several studies demonstrated that boosting the neurogenesis might be a viable option for alleviating the cognitive decline (Casse et al, 2018;Choi et al, 2018;Martinez-Canabal, 2014;Papadimitriou et al, 2018;Rodriguez and Verkhratsky, 2011), the potential benefits of neurogenic outcome in AD conditions requires further investigation and critical testing.…”